Schering
-
Bayer Schering Kicks Off Antihypertensive Study in Asia
Bayer Schering Pharma has held two investigators meetings in Beijing, China and Seoul, Korea to announce the start of ADVISE, the Asia Pacific trial – nifeDipine in combination with Valsartan to achIeve blood preSsure targEts, a major phase IV stud…
Schering | 27 January 2010
-
Genedata Provides Knowledge Management System to Bayer Schering
Genedata and Bayer Schering Pharma have announced a multi-year collaboration for the development and implementation of the Biologics Data Platform (BDP). The platform will support biologics data management and analysis at the latter’s R&D sites…
Schering | 08 January 2010
-
Affimed Joins the Molecular Imaging Technology Initiative
Affimed Therapeutics has announced a collaboration project with Bayer Schering Pharma, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Educati…
Schering | 04 March 2009
-
Schering-Plough Opens Research Centre
Schering-Plough Corporation has opened its Translational Medicine Research Centre (TMRC) in Singapore. The TMRC will be part of the Schering-Plough Research Institute (SPRI), the company’s human pharmaceutical research and development arm. The …
Schering | 20 February 2009
-
Schering-Plough Licenses Symyx Notebook
Schering-Plough Corporation has licensed the Symyx Notebook to equip the former’s research scientists across the company's global R&D operations. Schering-Plough will also collaborate with Symyx to develop within the notebook, a commercial metr…
Schering | 20 January 2009
-
Bayer Schering Pharma expands operations in Korea
Bayer Schering Pharma (BSP) says it aims to be among the top three multinational pharmaceutical companies in Korea. According to Andreas Fibig, chairman of the board of management, the company has achieved $9.9 billion in sales over the first nin…
Schering | 01 December 2008
-
Bayer Schering Pharma, NUS Inks Research Agreement
Bayer Schering Pharma and Yong Loo Lin School of Medicine, National University of Singapore have signed an S$3.5 million ($2.3 million) translational cancer research agreement in joint pre-clinical research collaboration in the field of oncology. …
Schering | 01 November 2008
-
Asenapine meets primary endpoint in long-term schizophrenia relapse prevention trial
Schering-Plough Corp says its psychopharmacologic agent asenapine has met the primary endpoint in a long-term schizophrenia relapse prevention trial. Asenapine, which is administered as a fast-dissolving sublingual tablet, is a psychopharmacologi…
Schering | 24 October 2008
-
Bayer Schering Pharma Grows in Asia Pacific
Bayer Schering Pharma Asia Pacific, a subsidiary of Germany based Bayer Schering Pharma AG, announced in March, 2008 that it achieved over 26% growth in their business over 2007. The Company is looking to grow further through its introduction of "…
Schering | 01 March 2008
-
Schering-Plough: Distinguished Partner Driving Singapore's Biomedical Sciences Sector
Schering-Plough Corporation, a global science-based health care company, has been conferred Singapore’s Distinguished Partner in Progress 2007 Award for its exceptional contribution to Singapore’s growing biomedical sciences industry. This is…
Schering | 24 August 2007
